Bio-Thera Solutions, Ltd.

688177

CNE100003R98

Biotechnology & Medical Research

End-of-day quote Shanghai S.E. Other stock markets 2026-03-10			5-day change	1st Jan Change
23.17 ^CNY	+3.25%		+4.32%	+0.13%

Feb. 26	Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 13	STADA and Bio-Thera Solutions Receives European Marketing Authorization for Gotenfia, A Biosimilar to Simponi	CI

Bio-Thera Solutions Obtains European Marketing Authorization

Published on 02/13/2026 at 05:58 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bio-Thera Solutions, Ltd.

Feb. 26	Bio-Thera Solutions, Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Feb. 13	STADA and Bio-Thera Solutions Receives European Marketing Authorization for Gotenfia, A Biosimilar to Simponi	CI
Feb. 13	Stada and Bio-Thera receive European marketing authorization for Gotenfia, a biosimilar to Simponi	RE
Feb. 13	Bio-Thera Solutions Obtains European Marketing Authorization	MT
Feb. 04	Bio-Thera Solutions Licenses Cancer Drug Candidate to Saudi Arabia's Avalon Pharma	MT
Feb. 04	Avalon Pharma contract sign off with Bio-Thera Solutions	RE
Feb. 03	Middle East Pharmaceutical Industries Co. Announces Contract Sign Off with Bio-Thera Solutions Inc	CI
Jan. 28	Bio-Thera Solutions Expects 2025 Loss to Narrow; Shares Down 4%	MT
Dec. 12	STADA And Bio-Thera Receive Positive CHMP Opinion For Golimumab Biosimilar Gotenfia	CI
25-10-28	Bio-Thera Solutions, Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-09	Bio-Thera Solutions Announces Expansion of Partnership with Intas Pharmaceuticals for BAT2506, A Proposed Biosimilar Referencing Simponi®?, Through Exclusive Commercialization and License Agreement in Canada	CI
25-10-09	Bio-Thera Solutions announces expansion of partnership with Intas Pharmaceuticals for BAT2506, a proposed biosimilar referencing Simponi (golimumab), through exclusive commercialization and license agreement in Canada	RE
25-09-15	Jamjoom Pharma strikes strategic deal with Bio-Thera for securing Cosentyx biosimilar in MENA	RE
25-09-11	Bio-Thera Solutions Grants Intas Pharma US Marketing Rights for Golimumab Injection	MT
25-08-26	The European Commission Approves Bio-Thera Solutions Inc.'s BAT2206 (Ustekinumab), a Biosimilar Referencing Stelara®	CI

Chart Bio-Thera Solutions, Ltd.

Duration

Period

688177: Dynamic Chart

Bio-Thera Solutions, Ltd. is a China-based company mainly engaged in the research and development of innovative drugs and biosimilars. The Company is committed to the development of a new generation of antibody drugs to treat cancer, autoimmune diseases, cardiovascular diseases and other major diseases that endanger human life and health. The Company's main products include adalimumab BAT1406, bevacizumab BAT1706, BAT8001, tocilizumab BAT1806, batifaban BAT2094, BAT8003 and so on.

Employees

1,251

Sector

Biotechnology & Medical Research

Calendar

Apr. 28 - Earnings release - Annual 2025

More about the company